Carolina Gentile
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carolina Gentile has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Agustín Ciapponi
Servicio de Medicina Familiar y Comunitaria, Hospital Italiano de Buenos Aires; Centro Cochrane Argentina, Instituto de Efectividad Clínica y Sanitaria
1 shared publication - Ariel Bardach
Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina
1 shared publication Charbel Viñolo Chaca
1 shared publication- Jamile Ballivian
Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina
1 shared publication - Jessica Ruiz-Baena
Àrea d’Avaluació i Qualitat, Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Catalunya, España
1 shared publication - Jhonatan R. Mejia
Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina
1 shared publication
Latest Publications
- 23 February 2026
- Published by S. Karger AG in Ocular Oncology and Pathology
- Vol. 12 (2) , 128-136
Extraocular Extension in Melanoma at an Ocular Oncology Unit in Buenos Aires
Introduction: Extrascleral extension (EOE) of uveal melanoma is a known negative prognostic factor, more frequently observed in medium to large tumors. Although EOE is typically limited in size, extensive cases present significant challenges in treatment planning, and the optimal management approach remains controversial. This study aimed to estimate the incidence of EOE in patients with uveal melanoma and analyze the prognosis of patients treated at the Italian Hospital of Buenos Aires from 2007 to June 2024. Methods: We conducted an observational, analytical, retrospective cohort study from 2007 to June 2024. Patients with EOE at diagnosis or during follow-up were identified. Epidemiological characteristics, tumor dimensions, timing of EOE, metastasis occurrence, and survival data were analyzed. Results: A total of 181 patients diagnosed with uveal melanoma were included, of whom twelve (6.62%) presented EOE, and 54.5% were male. The mean age was 64.41 years (SD 14.39). Six patients (50%) had EOE at diagnosis (average tumor thickness 9.51 mm, average diameter 17.7 mm), while six developed it during follow-up. The median time to event was 31.5 months (range: 8–120 months). Among these 12 patients, three developed metastases within the first year after diagnosis and treatment. Conclusions: EOE is a poor prognostic factor and tends to occur in larger tumors. It may be present at diagnosis or appear years later, reinforcing the need for long-term surveillance. Early identification is crucial to ensure appropriate treatment.
- 23 February 2026
- Published by S. Karger AG in Ocular Oncology and Pathology
- Vol. 12 (2) , 128-136
Extraocular Extension in Melanoma at an Ocular Oncology Unit in Buenos Aires
Introduction: Extrascleral extension (EOE) of uveal melanoma is a known negative prognostic factor, more frequently observed in medium to large tumors. Although EOE is typically limited in size, extensive cases present significant challenges in treatment planning, and the optimal management approach remains controversial. This study aimed to estimate the incidence of EOE in patients with uveal melanoma and analyze the prognosis of patients treated at the Italian Hospital of Buenos Aires from 2007 to June 2024. Methods: We conducted an observational, analytical, retrospective cohort study from 2007 to June 2024. Patients with EOE at diagnosis or during follow-up were identified. Epidemiological characteristics, tumor dimensions, timing of EOE, metastasis occurrence, and survival data were analyzed. Results: A total of 181 patients diagnosed with uveal melanoma were included, of whom twelve (6.62%) presented EOE, and 54.5% were male. The mean age was 64.41 years (SD 14.39). Six patients (50%) had EOE at diagnosis (average tumor thickness 9.51 mm, average diameter 17.7 mm), while six developed it during follow-up. The median time to event was 31.5 months (range: 8–120 months). Among these 12 patients, three developed metastases within the first year after diagnosis and treatment. Conclusions: EOE is a poor prognostic factor and tends to occur in larger tumors. It may be present at diagnosis or appear years later, reinforcing the need for long-term surveillance. Early identification is crucial to ensure appropriate treatment.
- 29 April 2025
- Published by Springer Nature in Eye
- Vol. 39 (10) , 2083-2089
Diagnostic utility of artificial intelligence software through non-mydriatic digital retinography in the screening of diabetic retinopathy: an overview of reviews
Objective To evaluate the capability of artificial intelligence (AI) in screening for diabetic retinopathy (DR) utilizing digital retinography captured by non-mydriatic (NM) ≥45° cameras, focusing on diagnosis accuracy, effectiveness, and clinical safety. Methods We performed an overview of systematic reviews (SRs) up to May 2023 in Medline, Embase, CINAHL, and Web of Science. We used AMSTAR-2 tool to assess the reliability of each SR. We reported meta-analysis estimates or ranges of diagnostic performance figures. Results Out of 1336 records, ten SRs were selected, most deemed low or critically low quality. Eight primary studies were included in at least five of the ten SRs and 125 in less than five SRs. No SR reported efficacy, effectiveness, or safety outcomes. The sensitivity and specificity for referable DR were 68–100% and 20–100%, respectively, with an AUROC range of 88 to 99%. For detecting DR at any stage, sensitivity was 79–100%, and specificity was 50–100%, with an AUROC range of 93 to 98%. Conclusions AI demonstrates strong diagnostic potential for DR screening using NM cameras, with adequate sensitivity but variable specificity. While AI is increasingly integrated into routine practice, this overview highlights significant heterogeneity in AI models and the cameras used. Additionally, our study enlightens the low quality of existing systematic reviews and the significant challenge of integrating the rapidly growing volume of emerging evidence in this field. Policymakers should carefully evaluate AI tools in specific contexts, and future research must generate updated high-quality evidence to optimize their application and improve patient outcomes.
- 29 April 2025
- Published by Springer Nature in Eye
- Vol. 39 (10) , 2083-2089
Diagnostic utility of artificial intelligence software through non-mydriatic digital retinography in the screening of diabetic retinopathy: an overview of reviews
Objective To evaluate the capability of artificial intelligence (AI) in screening for diabetic retinopathy (DR) utilizing digital retinography captured by non-mydriatic (NM) ≥45° cameras, focusing on diagnosis accuracy, effectiveness, and clinical safety. Methods We performed an overview of systematic reviews (SRs) up to May 2023 in Medline, Embase, CINAHL, and Web of Science. We used AMSTAR-2 tool to assess the reliability of each SR. We reported meta-analysis estimates or ranges of diagnostic performance figures. Results Out of 1336 records, ten SRs were selected, most deemed low or critically low quality. Eight primary studies were included in at least five of the ten SRs and 125 in less than five SRs. No SR reported efficacy, effectiveness, or safety outcomes. The sensitivity and specificity for referable DR were 68–100% and 20–100%, respectively, with an AUROC range of 88 to 99%. For detecting DR at any stage, sensitivity was 79–100%, and specificity was 50–100%, with an AUROC range of 93 to 98%. Conclusions AI demonstrates strong diagnostic potential for DR screening using NM cameras, with adequate sensitivity but variable specificity. While AI is increasingly integrated into routine practice, this overview highlights significant heterogeneity in AI models and the cameras used. Additionally, our study enlightens the low quality of existing systematic reviews and the significant challenge of integrating the rapidly growing volume of emerging evidence in this field. Policymakers should carefully evaluate AI tools in specific contexts, and future research must generate updated high-quality evidence to optimize their application and improve patient outcomes.